Patent application number | Description | Published |
20090281194 | Combinations for treating HIV-associated pain - The present invention relates to novel combinations suitable for the treatment or amelioration of pain of various genesis or aetiology, which comprise, as active ingredients, at least one cannabinoid receptor binding compound, in particular a cannabinoid receptor binding naphthalene derivative, and at least one opioid, to their preparation, to their use as medicaments and to medicaments comprising them. | 11-12-2009 |
20100041641 | USES OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 02-18-2010 |
20110212980 | COMBINATIONS FOR THE TREATMENT OF MIGRAINE - The present invention relates to novel combinations suitable for the treatment of migraine of various genesis or aetiology, which comprise, as active ingredients, at least one 5-HT | 09-01-2011 |
20120172346 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS - The invention concerns the use of a nicotinic acetylcholine receptor alpha 7 activators for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's Disease. | 07-05-2012 |
20120309742 | USE OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 12-06-2012 |
20130090346 | Use of 1H-quinazoline-2,4-diones - The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy. | 04-11-2013 |
20140163050 | Use of 1H-quinazoline-2,4-diones - The invention concerns the use of competitive AMPA receptor antagonists for the treatment or prevention of photosensitive epilepsy. | 06-12-2014 |
20140187600 | USE OF METABOTROPIC GLUTAMATE RECEPTORS - The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction. | 07-03-2014 |